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PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR (Last, First, Initial) 
Zalkow, Leon H. 
NAME OF ORGANIZATION 
Georgia Institute of Technology 1/1/79 1/1/80 P'61?°141(' 
FROM 
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TITLE (Repeat title shown In Item 1 on first paw 
Natural Antitumor Agents from the Senecioneae 
1. List publications: (a) published and not previously reported: (b) in press. Provide five reprints if not previously Submitted. 
2. List all additions and deletions in professional personnel and any changes in effort. 
3. Progress Report. (See Instructions) 
1) L. Gelbaum, L. H. Zalkow, and S. Bonetti, "Pyrrolizidine Alkaloids .from Senecio 	 
20th Annual Meeting of the American Society of Pharmacognosy, Purdue University, 
July 20-Aug. 3, 1979. 
L. H. Zalkow, L. T. Gelbaum, and D. Van Derveer, "Eremophilane Sesquiterpenes from Sene( 
aureus," J. Chem. Soc., Perkin I, 1542 (1979). 
L. H. Zalkow, S. Bonetti, L. Gelbaum, M. M. Gordon, B. B. Patil, A. Shani, and D. Van 
Derveer, "Pyrrolizidine Alkaloids from Middle Eastern Plants," J. Natural Products, 
in press. 
2) During the period covered the following personnel devoted the indicate amounts of time. 
Dr. L. Gelbaum, Research Scientist, 100% 
Ms. S. Bonetti, B.S., 50% 
3) During the period Jan. 1, 1979-Jan. 1, 1980 we have continued our work on the extracts 
of the Senecionaea and Crotaloria spectabilis. The following is a list of the Senecio 
species, collected in Colorado, that have been extracted with 95% ethanol and submitte 
for screening by the National Cancer Institute (NCI): 
Senecio triangularis Hooker 
S. streptanthifolius Greene 
S. integerrimus Cronquist, Var. exaltatus (Nutall) 
S. werneriaefolius A. Gray 
S. fremontii Cronquist, Var. blitoides (Greene) 
S. fendleri 	A. Gray 
S. crassulus A. Gray 
S. pseudaureus Greenman, Var. flavulus (Greene) 
S. atratus Greene 
S. dimorphophyllus Greene, Var. dimorphophyllus 
S. eremophilus (Rydberg) Greenman. Var. kingii 
Extracts from Crotalaria spectabilis Roth, Dicerandra linearfolia, Serenoa repens and 
Ophioglossium crotalophoroide have also been submitted for screening but results for the 
above plants have not yet been received. 
NCI screening for ethyl-l-hydroxy-4-oxo-2,5-cyclohexadiene-l-acetate (1) isolated fro 
Senecio anonvmus Wood (previously Senecio smallii Britt.) is now in progress. Preliminar 
KB screening results indicate significant activity with an ED
50 
of 3.3 x 10(0). The 
in vivo testing of 1 is now underway. 
Using high performance liquid chromatography we have been able to isolate and identif 
a rare pyrrolizidine alkaloid neosenkirkine (2), and a new pyrrolizidine alkaloid which 
the trans cinnamic acid ester of hydroxy senkirkine (3). These are in addition to 
senecionine (4), retrorsine (5), and senkirkine (6) previously isolated. 
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What is the mechanism of the antitumor effects of indicine N-oxide? The metabolism 
to indicine has clearly been shown not to be the mechanism (Powis, 1979). Many years 
ago it was suggested that pyrrolizidine alkaloids may interfere with purine metabolism 
in some unknown manner (Culvenor, 1968). It has been suggested that N-oxides act as 
biological oxygenating agents, particularly with respect to purines (Murray, 1976). 
It is known that the stacking properties of adenine nucleotides are absent in the 
corresponding nucleotide N-oxides (Mantsch, 1975). However, all of this is at 
present speculation and there is little eviderreto suggest how indicine N-oxide might 
act as an antitumor agent. 
Thus, with this proposal we hope to fill gaps in the knowledge of the mechanism 
of the antitumor effects of indicine N-oxide. Structure activity relationships 
will be developed by acylating retronecine a and thus discovering the critical feature 
necessary in the side chain of indicine N-oxide. Microbiological modifications of 
existing side chains will also be undertaken. We also plan to develop collagenase-
sensitive pepidyl pyrrolizidines as potential latentiated antitumor agents (Marguisee, 
1978). 
C. Progress Report: 4/1/78 - 4/30/80 
Dr. Leon H. Zalkow, Professor and Principal Investigator, 4/1/78-4/30/80, 25% time. 
Dr. Leslie T. Gelbaum, Research Scientist and Co-Principal Investigator, 
4/1/78-4/30/80, 100% time. 
Dr. Howard Deutsch, Research Scientist, 4/1/78-1/1/79, 25% time. 
Ms. S. Bonetti, B.S., Technician, 4/1/78-9/1/79, 50% time; graduate research 
assistant 	9/1/79-4/30/80, 	20% time. 
Dr. Maureen M. Gordon, Postdoctoral fellow, 3/1/80-4/1/80, 50% time. 
In the previous application we listed the following specific aims: (1) To 
fractionate and screen Senecio aureus and S. smallii; (2) To arrange for the collection 
of a number of species of Senecio and to process and screen as many of these as 
possible; (3) To attempt to shed some light on structure activity relationships by 
examining the NCI screening data on pyrrolizidine alkaloids and eremophilane 
sesquiterpenoids, if the latter exists; (4) To provide semi-synthetic pyrrolizidine 
alkaloid-like compounds for screening. We shall discuss each of these aims and our 
results. 
Plant Extracts and Compounds Submitted for Screening  
to NCI During Grant Period 4/1/78 - 2/29/80b  
Table 1 in Appendix A lists all plants, their extracts and the NCI assigned 
numbers submitted for screening during the period designated followed by copies of the 
actual screening data. The plants were collected and identified by four American and 
one Israeli botanist. The plants were processed according to the NCI procedure of 
2/22/77. Table 1 lists sixty (60) plant extracts and fractions and the two 
pyrrolizidine alkaloid N-oxides, echinatine N-oxide and europine N-oxide. Of the 
plant extracts screened only the ethanol extract of Senecio smallii (Senecio anonymous  
Wood) (NSC B837136) showed good activity T/C 133, dose 174 mg/Kg) and this activity 
was concentrated in the aqueous methanol fraction (NSC B837138, T/C 137, dose 50 mg/Kg). 
We have isolated six compounds from this methanol fraction, five of which are the 
b) This list also includes related pyrrolizidine alkaloid bearing plants from Israel 
obtained under grant CA-19946 (Carcinogenic Plants of the Dead Sea Area. 6/30/76-
6/30/79). No attempt was made to renew grant CA-19946 because our interest shifted 
to anti-tumor activity and in-particular to the semi-synthetic work described 
in this proposal (CA-23277). 
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pyrrolizidine alkaloids a : senecionine (NSC 089935), retrorsine (NSC 107659), the seco-
pyrrolizidine alkaloids senkirkine and neosenkirkine and the trans cinnamic acid 
ester of hydroxysenkirkine. Thus far we have had insufficient quantities of the seco 
alkaloids to screen but are in the process of obtaining larger quantities. 
In addition to the alkaloids, we have isolated from the methanol fraction, ethyl-1- 
hydroxy-4-oxo-2,5-cyclohexadiene acetate c (common name, jacaranone ethyl ester). The 
corresponding methyl ester jacaranone, isolated from Jacaranda caucana (Ogura, 1976) 
showed TC165 against P388 lympoctic leukemia at a dose of 62 mg/Kg. Jacaranonec is one 
of the simplest naturally occurring antitumor agents. Jacaranone ethyl ester (NSC 
289072) showed ED
50 
3.3 x 10(0) in the KB screen and is presently undergoing in vivo  
screening. 
As pointed out in our original grant application there is great danger in placing 
too much confidence in limited screening of plant extracts by NCI or any other 
screener. Thus, a number of examples exist where plant extracts showing negative 
screening results have yielded active compounds. However, in this case, with the 
experience we now have, we would proceed to isolate any new pyrrolizidine alkaloid 
available in a plant extract in reasonable amount and submit the pure alkaloid to NCI 
for screening, even if the plant extract showed little or no activity. This decision, 
of course, would be based on what our priorities were at a given time. Thus, 
obviously, an active plant extract would be of higher priority than an inactive one 
and a rational semi-synthetic alkaloid would be of highest priority. 
Compounds Isolated and Identified 4/1/78 - 4/30/80  
Table 2, Appendix B lists the thirty (30) novel compounds isolated and identified 
during the period indicated together with their structures. This list includes 13 
pyrrolizidine alkaloids, 9 sesquiterpene lactones and furans, 4 monoterpenes and 
4 miscellaneous aromatic compounds. Twenty two of these structures were determined 
using high resolution nuclear magnetic resonance spectroscopy-and high resolution 
mass spectrometry. The following seven structures were determined by single crystal 
X-ray diffraction: the pyrrolizidine alkaloids retronecine, heliotrine and 
monocrotaline, the eremophilane sesquiterpene 3a-angeloyloxy-9-oxo-10aH-furanoeremo- 
philane, the germacranolides 3E,8a-dihydroxy-6E,7a,11E H-germacran-4(15), 9(10)-dien-6, 
12- olide and the corresponding 3-oxo-olide and the sesquiterpene 14-oxo-1,2- 
dihydrocacalol.methyl ether. 
This is the first report of the isolation of these thirty compounds froM these 
plant sources. However, all of the pyrrolizidine alkaloids except for the trans-
cinnamic ester of hydroxysenkirkine have been reported from other plant sources. The 
following sesquiterpenes c are apparently new: 8a-ethoxy-10aH-eremophilenolide, 
3a-angeloxyloxy-9-oxo-10aH-furanoeremophilane, 116H-tatridin D (38,8a-dihydroxy-6EH, 
11EH-germacran-4(15), 9(10)-dien-6, 12-olide), 3-oxo-11EH-tatridin D, llaH-gallicin, 
11aH-1E-hydroxysant-4(14) en-6,12-olide C and this is the first report of S-truxinic 
acid diethyl ester in a plant. Also, the monoterpenes filifolide•A and filifolide•B 
are quite unusual. Since we have been informed that NCI prefers to have 1.5 g of 
pure compound for in vivo screening, we have not pursued the screening of most of the 
above mentioned compounds, except for the pyrrolizidine alkaloids, since they do not 
occur in large amounts and the crude plant extracts did not show sufficient activity 
to warrant recollection of the plant material. Interestingly, europine N-oxidea 
and echinatine N-oxidea were found to be comparable in activity to indicine N-oxide 
against P388 lymphocytic leukemia tumors on direct comparisons under identical 
conditions (Zalkow, 1979). However, europine N-oxide and echinatine N-oxide are 
c) The structure of this compound can be found in Table 2 of Appendix B. 
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derived from the base heliotridine while indicine N-oxide is derived from retronecine. 
These two bases differ in stereochemistry at C-7 (a0H in heliotridine, P.OH in 
retronecine). In section D. Methods, we discuss the significance of these results, 
together with literature evaluations in the rationale for the semisynthetic work 
utilizing retronecine. 
Critical Evaluation of NCI Screening Data  
of Pyrrolizidine Alkaloids and Derivativesd  
Tables 3 and 4 of Appendix C show the pyrrolizidine alkaloids, their N-oxides and 
various derivatives that have previously been screened by NCI for activity against 
P388 lymphocytic leukemia tumors (PS). Among those that show significant activity 
(T/C) are: (-) and (+) 3,8-didehydroheliotridine (NSC 116336 and 144848), fulvine 
(NSC 089932), crispatine (NSC 089933), monocrotaline a-epoxide (NSC 113087), 
indicine N-oxide (NSC 132319), heliotrine N-oxide (NSC 030621), laaiocarpine N-oxide 
(NSC 035046), monocrotaline N-oxide (NSC 108378) and jaconine hydrochloride 
(NSC 030624). These data suggest that, in general, the N-oxides are more effective 
against the PS tumor system than the corresponding free amines. 
The fact that indicine N-oxide has reached clinical evaluation is extremely 
significant. 
To place this in proper perspective it should be noted that between 1965 and 1978 
only 13 plant products or semisynthetic derivatives were filed by NCI with the FDA 
as candidates for clinical trials (indicine N-oxide being the most recent one), and 
of these, six have been since dropped because of uncontrolled toxicity, no therapeutic 
effect or insufficient activity (Suffness, 1979). 
A surprising but apparently significant observation that arises from perusal of 
Tables 3 and 4 (Appendix C) is the effect of the vehicle used for administering the 
alkaloidal material. Not all of the alkaloidal materials were administered under the 
same conditions and some of the vehicles previously used have now been discontinued. 
Thus, some of the screening would have to be repeated to be meaningful. 
Since indicine N-oxide has undergone the most extensive testing, it is possible to 
compare the effects of different vehicles on the efficacy of this drug. Seventy (70) 
experiments were carried out with indicine N-oxide in the PS tumor system employing 
intraperitoneal injections. Fifty one (51) of these used water, while nineteen (19) 
used normal saline as the vehicle. An average of the T/C values and optimum doses 
gave values of T/C 174 and 513 mg/Kg for water and T/C 120 and 726 mg/Kg for saline. 
However, not all of the testing was carried out under exactly the same conditions. 
It is clear that the optimum doses for water are considerably lower than those for 
saline. The data for indicine N-oxide thus shows that the vehicle water gives a 
higher survival rate at a significantly lower dose level. Finally, it can be seen 
that most of the pyrrolizidine alkaloids were not tested under these conditions and 
in the future we suggest water be used as the vehicle for the semisynthetic N-oxide-
analogs we submit for screening. 
Semisynthetic Pyrrolizidine Alkaloid Analogs  
In order to determine what features of the (-)trachelanthic acid side chain of 
indicine N-oxide were significant for antitumor activity, a semisynthetic program was 
initiated. Monocrotaline a was isolated from seeds of Crotalaria spectabilis Roth.  
obtained from South Georgia and hydrolysis of monocrotaline yielded the base 
retronecine, identical to that derived from indicine. 	The retronecine thus obtained 
was then acylated with various acids. 
d) These data were kindly supplied by Dr. Matthew Suffness, Natural Products Branch, 
Developmental Therepeutics Program, Division of Cancer Treatment, National Cancer 
Institute, Silver Spring, Maryland 20910 
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In order to develop the synthetic techniques necessary to prepare the semisynthetic 
pyrrolizidine alkaloids we have thus far investigated the syntheses of twenty-one 
analogs (see Section D. Methods) in milligram quantities. We have spent approximately 
six months in developing the synthetic methods, isolation procedures and characteri-
zation methods and are now in a position to prepare these analogs in gram quantities 
for NCI screening. The details of our semisynthetic analog work can be found in 
Section D. Methods since it forms the basis of a major part of our future plans. 
Publications and Unpublished Results  
Publications and Official Presentations: 
"Eremophilane Sesquiterpenes from Senecio aureus," Leon H. Zalkow, -Leslie T. Gelbaum 
and Donald Van Derveer, J. Chem. Soc., Perkins Transactions I, 1542 (1979) e . 
"Pyrrolizidine Alkaloids from Middle Eastern Plants," L. H. Zalkow, S. Bonetti, L. 
Gelbaum, M. M. Gordon, B. B. Patil, A. Shani and D. Van Derveer, J. Natural Products, 
42, 603 (1979) e . 
"A Phytochemical Investigation of Artemesia herba alba," L. H. Zalkow and M. M. Gordon, 
Proceedings of the 20th Annual Meeting of the American Society of Pharmacogonosy, 
July 29-Aug. 3, 1979, Purdue University, J. Natural Products, 42, 681 (1979). 
"Pyrrolizidine Alkaloids from Senecio smallii," Leon Zalkow, Leslie Gelbaum and 
Sandra Bonetti, Proceedings of the 20th Annual Meeting of the American Society of 
Pharmacognosy, July 29-Aug. 3, 1979, Purdue University, J. Natural Products, 42, 
688 (1979). 
"Germacranolides from Artemisia herba alba," L. H. Zalkow, M. M. Gordon and 
D. Van Derveer, 178th ACS National Meeting, Washington, D. C., September 10-13, 1979. 
"Secondary Plant Metabolites from Senecio smallii," Leslie Gelbaum and Leon H. Zalkow, 
30th Southeastern Regional Meeting, American Chemical Society, Savannah, Ga., 
Nov. 8-10, 1978, Abstract 215. 
Unpublished Material: 
A perusal of Table 2 in Appendix B indicates that we have isolated and proven the 
structures of a number of compounds for which we have not yet published papers. We 
have completed publishable work on the following and manuscripts should be available 
soon: 
1. "The Terpenes of Senecio smallii". 
2. "Pyrrolizidine Alkaloids of Senecio smallii". 
3. "The X-Ray Structures of Monocrotaline and Retronecine". 
4. "A Phytochemical Investigation of Artemisia judaica". 
5. "Germacranolides of Artemisia herba alba". 
Changes in Project's Specific Aims from Previous Application  
In the previous application we emphasized screening of plants, particularly from 
the genus Senecio in hopes of uncovering new leads. We have done this and, in 
addition, have received a number of other genera containing pyrrolizidine alkaloids 
and also potentially interesting plants which were physically accessible to the 
botanists (Artemisia, etc.) in their collections of the pyrrolizidine alkaloid bearing 
e) Reprints of these papers are provided in Appendix D. 
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plants. After examining a rather large number of plants and having isolated quite a 
large number of novel natural products, our conclusion is that this procedure should, 
in the future, be secondary and our primary objective should now be to prepare semi-
synthetic analogs. This, we believe and discuss in detail in the next section 
(D. Methods), will lead to a better understanding of the mechanism of action of 
indicine N-oxide and therefore to the ultimate goal - the discoveryof better antitumor 
agents. 
Also in the previous application we considered developing a structure activity 
relationship for eremophilane sesquiterpenoids, which also occur rather commonly in 
the Senecio. We do not now feel this should be a high priority goal since the species 
which contain these terpenes did not, in our hands, show sufficiently high activity 
to justify recollection. We have in hand a few such isolated compounds (see Appendix 
B, Table 2) but in insufficient amounts to get reliable in vivo screening data. We 
shall however request KB screening by NCI. 
D. Methods: We will continue to submit plant extracts from the tribe Senecioneae and, 
in addition extracts from other pyrrolizidine bearing plants (Heliotropioideae and 
Boraginoideae) for screening by NCI. The plants will be collected and identified by 
botanists from Emory University, University of Georgia, Kansas State University, 
Hebrew University of Jerusalem, Valdosta State College, Virginia Polytechnic Institute 
and University, and Gordon Junior College who have performed this function for us in 
the past. The air-dried plant, after shipping to the Natural Products Laboratory 
at the School of Chemistry, Georgia Institute of Technology will be ground and 
extracted. We are well equipped for these operations, having all size Soxhlet 
extractors including three of five kilogram capacity. 
Recently NCI has revised its recommended extraction procedure (5/24/78) for 
extracts to be supplied to them. This new procedure requires extraction of the dried 
plant material with 95% ethanol followed by partitioning of the residue obtained on 
removal of the ethanol between chloroform and water. They then recommend only screening 
the chloroform fraction. While this procedure may be of general use, it is clearly 
a mistake for pyrrolizidine alkaloid-bearing plants, since almost all of them, if 
not all, contain water soluble N-oxides (Bull, 1968), which as previously mentioned 
are of more importance than the free bases in regard to antitumor activity. Therefore, 
we will process the water fraction for N-oxides and, of course, screen the isolated 
alkaloids. 
Because, as previously mentioned, it is not uncommon in this area, that inactive 
crude plant extracts yield active alkaloids (this appears to be due to a concentration 
effect, the alkaloids being present in low concentration and being active at high 
concentration), we plan to screen the crude 	 95% ethanol extracts,chloroform 
and water partitions, and the isolated alkaloid fractions in each case. 
Isolation of the alkaloid fractions will be conducted as follows. The free bases' 
will be isolated from the chloroform partition residue by extraction with 2N sulfuric 
acid followed by basification of the sulfuric acid extract with ammonium hydroxide, 
and reextraction back into chloroform. Evaporation of the chloroform will yield the 
crude alkaloid fraction which will be screened. If this fraction shows activity it will 
be separated by high performance liquid chromatography into individual alkaloids, 
each of which will be screened. If the crude alkaloid fraction is found to be 
inactive, no further separation of this material will be undertaken. 
The previously mentioned water partition, which contains the pyrrolizidine alkaloid 
N-oxides, will be reduced with zinc and sulfuric acid (Bull, 1968), then the solution 
will be basified with ammonium hydroxide and extracted with chloroform to give the free 
bases which will be processed as above. 	The free bases will then be converted 
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into their corresponding N-oxides with hydrogen peroxide (Bull, 1968) or micro-
biologically (see below). This will insure that we do not miss any unusual alkaloids 
in the water fraction during the above separation procedure. 
Separations of crude - lkaloid fractions will be done by high performance liquid 
chromatography. We have become very proficient at separating these materials using 
a combination of silica gel and reverse phase HPLC columns. We are able to process 
twenty (20) g Of crude alkaloid at one time through our Waters 500 Preparative HPLC 
instrument and then we are able to prepare analytically pure samples in gram quantities 
by further high pressure HPLC using both ultraviolet and refractive Index detectors. 
Since we also have developed the capability to prepare our own HPLC columns (reverse 
phases C-18, C-8, C-2; silver nitrate on silica) we are convinced we can separate 
any natural alkaloid fraction into its components. 
Once the alkaloids have been isolated in pure form, their characterizations will 
be done using the usual techniques, but in particular, high resolution 1H and 13C 
nuclear magnetic resonance spectrometry (100 and 300 mHz) and high resolution mass 
spectrometry. We have already gained a great deal of experience using these 
techniques with numerous pyrrolizidine alkaloids (Zalkow, 1979) and are confident 
that we can now pick up small variations in the necic acid side chains of the alkaloids 
by careful examination of the high resolution NMR spectra. 
In the School of Chemistry at the Georgia Institute of Technology single crystal 
X-ray diffraction is a routine service and thus we will get X-ray structures of all 
suitable crystalline alkaloids. We have already done this for heliotrine, monocrotaline 
and the base retronecine. Computer drawn pictures of these three substances are 
indicated below (the drawing of monocrotaline is the mirror image of the natural 
material). We plan to use the information from X-ray analyses to try and determine 
the structural and conformational features that make indicine N-oxide such a good 
antitumor agent as compared to, for example, heliotrine N-oxide.. In order to do 
this we need to obtain the X-ray structure of indicine and compare it to that of 
heliotrine and then we need to compare the X-ray structures of the N-oxides to each 
other and to their respective bases. Thus an examination of the computer drawn 
picture of heliotrine clearly indicates the endo puckering of the pyrrolizidine ring 
and the absence of intramolecular hydrogen bonding between the methoxy oxygen (05) 
and the OH group (01) at C-7. What is the situation in indicine, which differs from 
heliotrine (see structures below) in stereochemistry at the C-7 hydroxyl group and in 
having a free hydroyl group at C-12 instead of a methoxyl? Thus, is indicine more like 
monocrotaline? How much effect does the N-oxide have on conformation? Of course all 
of these arguments will be based on crystal structures and may not apply to these 
molecules in solution. However, we may be able to say something about the relative 
ease with which indicine and heliotrine form macrocyclic hydrogen bonds. 
Retronecine 
H 3C OH 
• 	i 
CH 3 -CH—C—C-CH3 
CO OH CO 
0 CH 2-0 
Monocrotaline 
(retronccine, monocrotalic acid)  
HO CH 2 OH 
\NJ 




HO CH 2-O-CO-C-CH-CH 3 
OH 
\,N,/ 
H 3C CH, 
HC OCH„ 




(heliotridine. heliotric acid) 
See next page for computer drawn pictures. 
Indicine 
(retronecine, 
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Based on our experience during the first two years of this grant, we conclude that 
the most rapid method of discovering new antitumor agents belonging to the pyrrolizi-
dine alkaloid class will be by semisynthetic methods. Our reasoning is based on the 
following observations: (1) screening a large number of plants seldom yields new 
and novel pyrrolizidine alkaloids. However, the screening is still worthwhile in 
the long run because when a new alkaloid is found, it will usually be complicated 
enough as to not be synthetically accessible and will provide a model for semi-
synthetic compounds. (2) The state of the art in synthetic organic chemistry is 
such that we cannot expect totally synthetic pyrrolizidine alkaloids in the near 
future. A number of the most distinguished organic chemists in America have been 
working for several years on the syntheses of the bases retronecine (see p. 	) 
and its C-7 epimer, heliotridine,and apparently the most we can expect from these 
efforts, at this time, will be academic syntheses without the provision of any 
reasonable quantitites of these materials. (3) Retronecine and its N-oxide is 
available to us in hundreds of gram quantities as by-products from the isolation 
of indicine N-oxide from Heliotropium indicium (see letters in Appendix E). 
(4) Preliminary studies in our laboratory (see C. Progress Report) and by others 
(Atal, 1978; Hoskins, 1977; Culvenor, 1976) have shown that we can make gram 
quantities, enough for in vivo  screening by NCI, of a large number of pyrrolizidine 
alkaloids by acylation of retronecine derived from natural sources. 
Which semisynthetic compounds should be prepared? The goal is obviously to 
separate the toxic effects of pyrrolizidine alkaloids from the antitumor activity. 
This, of course, is easily said but the solution to this is one of the major problems 
in cancer research. There has been extensive work on the toxic action of pyrrolizidine 
alkaloids (McLean, 1970; Culvenor, 1976; Schoental, 1979) and the structural features 
of the alkaloids which enhance toxicity are known, but the biochemical basis of the 
toxicity is still not very well understood. Almost nothing is known of the mechanism 
of the antitumor activity (Powis, 1979). 
Diesters of heliotridine and retronecine are about 4 times as toxic as the 
respective mono-esters and heliotridine esters are 2-4 times as toxic as retronecine 
esters (Culvenor, 1976). Thus, fortunately, the readily available base retronecine 
is the base of choice and chemically the C-9 monoester is readily prepared because 
of the greater reactivity of the C-9 allylic hydroxyl group (Hoskins, 1977). There-
fore, monoesters of retronecine, esterified at C-9, which are analogs of indicine 
should be readily available. N-oxides are substantially less toxic than their 
corresponding free bases (Culvenor, 1976) when administered by the intraperitoneal 
route, but not when given orally since they are quickly reduced to the alkaloid 
in the gastro-intestinal tract, because of their decreased lipid solubility. The 
synthetic analogs, just as the natural alkaloids, can be readily oxidized to the 
N-oxides with hydrogen peroxide (Bull, 1968). 
The toxicity, and perhaps the antitumor activity, of the pyrrolizidine alkaloids 
are apparently due to metabolites of the pyrrole type formed by microsomal mixed 
function oxidases (Mattocks, 1972). It has been suggested that these pyrroles 
act as alkylating agents as illustrated in the diagram (Mattocks, 1972). 
The interst in pyrrolizidine alkaloids as antitumor agents apparently arose from 
observations of the long-lasting effect of single doses, possibly related to cell 
division (McLean, 1970). Liver cells suffering the long term effects of pyrrolizidine 
alkaloid poisoning accumulate an excess of nuclear chromatin and fail to divide 
(Downing, 1968). The divorce of DNA synthesis from cell division is extremely signifi-
cant. 	Pyrrolizidine alkaloids are capable of causing chromosome breakage in the 
growing cells of the root tip of the onion and of wild peas (Avanzi, 1962). 	Cysteine 
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Hypothetical fate of a reactive pyrrolic metabolite (dihydropyrrolizine ester) in the 
liver of a rat 
number of mutants in successive broods of Drosophilia and the effect is dose-
dependent (Clark, 1960; Cook, 1966). Pyrrolizidine pyrroles have mutagenic activity 
in Drosophilia and Aspergillus and are capable of inhibiting the DNA virus, infectious 
bovine rhinobracheitis (McLean, 1970). It has been speculated that pyrrolizidine 
pyrroles act by cross linking DNA, but experimental evidence on this point is scant. 
Culvenor et al. (Culvenor, 1969) showed that labelled alkaloid transferred its label 
to rat nucleic acids in amounts roughly equivalent to one molecule of alkaloid per 
molecule of DNA. 	On the next page is a diagram of how these pyrroles might 
interfere with DNA replication (McLean, 1970). 	 We have no indication of 
how the cross-linking actually occurs - perhaps via the C-7 hydroxyl group or the 
cross-linking may involve one covalent bond and one hydrogen bond. 
The above discussion illustrates the problem with most antitumor agents - their 
lack of specificity. We would like, ultimately, to design an antitumor agent in 
inactive or latentiated form which is activated by an enzyme associated with the 
targeted tumor tissue (Marguisee, 1978). We discuss our plans along this line later 
in the proposal. Meanwhile, we will describe more immediate, short range work 
which should provide useful structure-activity information. 
The necic acid side chains of the pyrrolizidine alkaloids are apparently not 
metabolized into active compounds. Their role in toxicity, antimitotic and anti-
tumor activity is not understood. However, their role is obviously critical as 
seen by the fact that indicine N-oxide is less toxic and a better antitumor agent 
than closely related alkaloids with the same necine base (retronecine) and slightly 
different necic acids. Mattocks (Mattocks, 1973), one of the leading authorities 
in the world on pyrrolizidine alkaloids has clearly stated the case for preparing 
semisynthetic analogs as proposed here - "Thus it is evident that by varying the acid 
moiety the tissue distribution and toxic effects of pyrrolic metabolites can be 
altered. This has relevance to the design of possible cytotoxic and antimitotic 
derivaties for antitumor therapy." 
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Cross-linking here 	Cross-linking here allows 
prevents DNA synthesis. 	DNA synthesis, but prevents 
division. 
• 
D. 	 E. 
Cross-linking here can lead either to 
Chromosome breakage E. , or to an 
arrested mitosis D. 
A. 
Normal process of C N A 
replication with separation 
of Chromatids. 
A, normal replication of DNA and separation of chromatids; B, cross 
of DNA here prevents replication; C, cross-linking of DNA here allows replication but 
prevents separation of chromatids; D, crows linking here allows partial DNA replicatiuu 
and leads to arrest of mitosis or to chromosome breakage, E. 
Table 1 lists 21 semisynthetic analogs which we have recently prepared on a small 
scale in order to develop our synthetic procedures, isolation techniques and character-
izations. The selection of compounds was designed to give an initial fairly broad 
spectrum of compounds so that the screening data would be instructive in terms of 
structure-activity relationships. These analogs were prepared by coupling retronecine 
with the appropriate acid using 1,1'-carbonyldiimidazol (CDI) (Hoskin, 1977) as the 
coupling agent. None of the compounds in Table 1, except for one have been previously 
reported, and none have been screened for antitumor activity. The synthetic procedure 
can, in principal, yield three products in each case, the C-7 and C-9 monoesters and 
the 7,9-diester. In fact, the reactivity of the C-9 hydroxyl group is so much greater 
than the C-7 hydroxyl group, that in almost every case the C-9 isomer, the desired 
isomer, predominates to such an extent that we only isolate it. Two exceptions can be 
seen in Table 1. Thus, benzoic acid yielded the C-9 monoester 6 and the diester 7 and 
phenylacetic acid gave the C-9 ester 8 and C-7 ester 9. 
Compounds 1 through 16 of Table 1 were readily purified by HPLC using activity III 
alumina and they have been characterized by high resolution FT NMR analyses and high 
resolution mass spectral analyses using chemical ionization and exact mass determinatbn. 
Our next goal is to prepare these compounds in gram quantities for screening by NCI 
(see Appendix E). Where possible, the analogs will be converted into their N-oxides 
which will also be screened. 
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Compounds 1-5 and their N-oxides will provide leads on the effect of 
lipophilicity, steric bulk near the acyl carbonyl and the effect of a conjugated 
double bond. The N-oxides of 1,2, 4 and 5 should present no problem in preparation by 
the usual method with hydrogen peroxide. However, this method when used with 3 would 
be expected to yield the epoxide N-oxide, which would be an interesting compound for 
screening in its own right. In conjunction with Professor S. Crow a microbiologist 
from Georgia State University, we have found what appears to be a good organism for 
specifically converting pyrrolizidine alkaloids to N-oxides. Thus, we expect to 
explore this microbiological oxidation further with the goal of using it to prepare 
N-oxides of those compounds which have other groups sensitive to oxidation with 
hydrogen peroxide. 
Compounds 6-14 all contain one or more phenyl rings in the acyl moiety. A 
comparison of the screening data of 8 and 9 will measure the relative effects of 
acylation at C-9 and C-7 respectively, while a comparison of the data from 6 and 7 
will give an indication of the effect of mono vs diacylation. A comparison of the data 
from 6, 8 and 10 will give information on the effect of moving the phenyl group further 
away from the carbonyl group. Compound 11 will test the effect of a second phenyl 
group, 12 will measure the effect of a conjugated phenyl group (compared to 10) and 
13 will measure the effect of the strong electron withdrawing chlorine atom in the 
ortho position (compared to 6). Compound 15 will measure the effect of a pyridine 
ring vs a phenyl ring (compare with 6). 
Compound 14 is particularly interesting as seen when its side chain, 2-pheny1-2- 
hydroxybutyric acid, is compared with the (-) trachelanthic acid side chain of 
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(-) trachelanthic acid 	(±) 2-phenyl-3-hydroxybutynic acid 
hydroxyl group is missing.(±) 2-Phenyl-2-hydroxybutyric acid is readily prepared by 
the addition of HCN to propiophenone followed by acid hydrolysis of the cyanohydrin. 
We plan to prepare a number of analogs related to 14 in which the acyl side chain most 
closely resembles that in indicine. Compound 14 was prepared as the first model in 
this caries because the above described reaction is so facile in this case. We, of 
course, do not know at this time whether or not the chirality of the side chain is 
very important. 
Compound 16 was prepared inadvertently as a by-product in the preparation of 3 
and apparently arises from the reaction of 3 with imidazole, from the CDI coupling 
reagent, or prior reaction of S-methyl-crotonic acid with CDI to give the Michael 
adduct. It's unusual structure appears to be of interest to NCI (see Index E). 
Compound 17 deserves special note. We had previously prepared the acid, tetrahydro-
4-methylene-5-oxo-3-furoic acid (NSC 124901) which has been of great interest to NCI 
since it has shown good activity in the PS system (T/C 148, 32 mg/Kg). We have just 
sent NCI an additional 25 g of this acid for more extensive screening. We therefore 
decided to couple this acid with retronecine. At present this product still requires 
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As long ago as 1953, latentiated nitrogen mustards were prepared (Danielli, 1954). 
At that time, these latentiated antitumor agents could not exploit the differences 
between normal and tumor tissue. Recently, workers (Marguisee, 1978) have attempted 
to exploit tumor-associated collagenase by using a nitrogen mustard inactivated by a 
collagenase-sensitive peptide. Collagenase is a highly specific collagen-degrading 
enzyme which is elaborated by many, if not all, slow-growing tumors. Tumor-associated 
collagenase cleaves the peptidyl acyl moiety Cbz-L-Pro-L-Leu-Glz-L-Pro-Glz (W-ansch, 
1963). Thus, we ultimately plan to attach this acyl peptidyl group to retronecine. 
However, at this stage we are beginning by attaching single amino acids to the C-9 
position of retronecine and compounds 18-20 of Table 1 illustrate our initial 
efforts. Compounds 18-21 were prepared by coupling the N-t-butoxycarbonyl (t-BOC) 
derivatives of the appropriate amino acids with retronecine in the presence of CDI. 
The t-BOC group is later removed by reaction with dry HC1 in dioxane. We next plan 
to prepare di and tripeptide derivatives and finally the target pentapeptide mentioned 
above. This pentapeptide will be prepared as previously described (Marguisee, 1978) 
and coupled to retronecine. 
Finally we plan to prepare dihydropyrrolizine derivatives (pyrroles)of the 
semisynthetic pyrrolizidine alkaloids according to literature procedures (Culvenor, 
1969). As previously mentioned, the dihydropyrrolizidine (pyrrole) compounds are 
known metabolic products of pyrrolizidine alkaloids, but we do not know if they are 
the active antitumor agents or if metabolism must occur in vivo to produce the 
desired activity. 
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